Combined Therapeutics to Present at 11th International mRNA Health Conference
BOSTON, Oct. 25, 2023 /PRNewswire/ — Combined Therapeutics Inc. (CTx), a privately held biotechnology company developing the next generation of mRNA therapeutics with a novel modified-mRNA platform to treat and prevent infectious diseases and cancer, today announced the participation of Romain Micol, M.D., MPH, Ph.D., President and CEO of Combined Therapeutics, as a speaker at the 11th…
Combined Therapeutics CEO, Romain Micol, to Present at the World Vaccine Congress Europe 2023
BOSTON, Oct. 11, 2023 /PRNewswire/ — Combined Therapeutics Inc. (CTx), a privately held biotechnology company developing the next generation of mRNA vaccines and therapeutics with a novel modified-mRNA platform to treat and prevent infectious diseases and cancer, today announced the participation of Romain Micol, M.D., MPH, Ph.D., President and CEO of Combined Therapeutics, as a speaker at the…
Combined Therapeutics to Present its Next-Generation mRNA-Based Vaccine Platform at the World Vaccine Congress 2023
BOSTON, March 30, 2023 /PRNewswire/ — Combined Therapeutics Inc. (CTx) today announced its participation in the upcoming World Vaccine Congress 2023, taking place in Washington, D.C., April 4-6, where it will present its cutting-edge mRNA-based vaccine technology MOPCTx in a poster presentation and oral…
Combined Therapeutics Granted Patent for its mRNA Vaccine Platform by USPTO
BOSTON, March 13, 2023 /PRNewswire/ — Combined Therapeutics Inc. (CTx) today announced its intellectual property position reinforcement in mRNA vaccine technology with the issue of U.S. Patent 11,596,685 by the United States Patent and Trademark Office (USPTO) on March 7,…
Combined Therapeutics Expands Board of Directors with Appointments of Biopharma Industry Veterans Paul Wotton, Robert Ruffolo and Kevin F. McLaughlin
BOSTON, March 8, 2023 /PRNewswire/ — Combined Therapeutics Inc. (CTx), a privately held biotechnology company developing the next generation of mRNA therapeutics with a novel modified-mRNA platform to prevent and treat infectious diseases and cancer, today announced the appointment of three highly accomplished biopharma executives to its board of directors: Paul Wotton, Ph.D.;